






Bioorganic & Medicinal Chemistry Letters

Volume 10, Issue 8, April 2000, Pages 719–723



Heterocyclic bibenzimidazole derivatives as topoisomerase I inhibitors

- [Song Jin^a](#),
- [Jung Sun Kim^a](#),
- [Sai-Peng Sim^b](#),
- [Angela Liu^b](#),
- [Daniel S. Pilch^{b, c}](#),
- [Leroy F. Liu^{b, c}](#),
- [Edmond J. LaVoie^{a, c}](#)  
- ^a Department of Pharmaceutical Chemistry, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854-8020, USA
- ^b Department of Pharmacology, The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
- ^c The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA

Abstract

A series of 2'-heterocyclic derivatives of 5-phenyl-2,5'-1*H*-bibenzimidazoles were evaluated for topoisomerase I poisoning activity and cytotoxicity. Topo I poisoning activity was associated with 2'-derivatives that possessed a hydrogen atom capable of hydrogen bond formation, suggesting that the interatomic distances between such hydrogen atoms and the heteroatoms on the adjacent benzimidazole influence activity.